DMK Pharmaceuticals Corporation

The momentum for this stock is not very good. DMK Pharmaceuticals Corporation is not very popular among insiders. Tradey thinks it is not wise to invest in DMK Pharmaceuticals Corporation.

News

Head to Head Survey: DMK Pharmaceuticals (NASDAQ:DMK) versus Atreca (NASDAQ:BCEL)

Zolmax Atreca (NASDAQ:BCEL Get Free Report) and DMK Pharmaceuticals (NASDAQ:DMK Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two...\n more…

DMK Pharmaceuticals regains full rights to commercialize ZIMHI

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI

Globe Newswire Company seeking commercialization partnerships in the United States, Canada, and Europe to expand revenue generationSAN DIEGO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation...\n more…

Maxim Group Begins Coverage on DMK Pharmaceuticals (NASDAQ:DMK)

Ticker Report Maxim Group initiated coverage on shares of DMK Pharmaceuticals (NASDAQ:DMK Free Report) in a report issued on Thursday, Benzinga reports. The firm issued a buy rating and a $1.50 price...\n more…